Medication Use & Chronic Pain Control: Managing Tolerance, Dependence, Addiction & Aberrant Medication Taking Behavior

Similar documents
Addressing the Opioid Epidemic: Prescribing Opioids for Non-Cancer Pain

No disclosures for any of the speakers!

Pain and Chemical Dependency Fathy Nasr

Patient-reported and interview-rated abuse-related outcomes

Pain Management and Addiction: Clinical Challenges

Disclosures. Ms. Walsh has nothing to disclose Ms. Broglio is on the speaker s bureau for Genentech and Meda Pharmaceuticals

Opioid Analgesics: Responsible Prescribing in the Midst of an Epidemic

Use of Opioids for Chronic Non Malignant Pain (CNMP)

Risk Reduction Strategies in Pain Management

Opioids: Use and Misuse/Steven Feinberg, MD; Scott Levy, MD, MPH, FACOEM

Medication Management

Chronic Pain Pharmacist role in the clinic

Pain, Opioids, & Substance Use Disorders

Colorado State Board of Medical Examiners Policy

4/3/2018. The Role of Pharmacists in the Safe Prescribing of Opioids: Having the Tough Talks with Patients and Prescribers. Learning Objectives

Acupuncture. Opioid Prescribing: Pitfalls for Occupational Medicine Physicians

THE PROS & CONS OF THE CDC GUIDELINES FOR SAFE OPIOID PRESCRIBING

Rule Governing the Prescribing of Opioids for Pain

HOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain

The Challenging Patient with Chronic Opioid Usage MD ACP Meeting

Opioids and Pain: Identifying, Assessing and Responding to an Aberrant Behavior

John Murphy DO, MS Lynx Healthcare

Universal Precautions and Opioid Risk. Assessment. Questions: How often do you screen your patients for risk of misuse when prescribing opioids?

Opioids in Pain and Addiction

Opioids in the Management of Chronic Pain: An Overview

Approaches to Responsible Opioid Prescribing. The Opioid Naïve Patient

Fire the Molecule, Not the Patient! From Irresponsible Prescribing to Universal Precautions. Douglas Gourlay, MD, MSc, FRCPC, FASAM

INFORMED CONSENT FOR OPIOID TREATMENT FOR NON-CANCER/CANCER PAIN Texas Pain and Regenerative Medicine

Organizing your Practice for Efficient Pain Assessment. Session #4 Roman D. Jovey, MD

Proposed Revision to Med (i)

Standard of Practice for Prescribing Opioids (Excluding Cancer, Palliative, and End-of-Life Care)

An unpleasant sensory and emotional experience associated with actual or potential tissue damage.

Missouri Guidelines for the Use of Controlled Substances for the Treatment of Pain

Chronic Pain Management in the Primary Care Setting

MEDICATION MANAGEMENT AGREEMENT

KANSAS Kansas State Board of Healing Arts. Source: Kansas State Board of Healing Arts. Approved: October 17, 1998

Chronic Pain, Opioids, & Addiction: Assessing and Managing Risk

Opiate Use Disorder and Opiate Overdose

Section I. Short-acting opioid Prior Authorization Criteria

Oklahoma. Prescribing and Dispensing Profile. Research current through November 2015.

Opioid Review and MAT Clinic CDC Guidelines

Jennifer Wyman, MD, Academic Lead, Opioids Clinical Primer Assistant Professor, Dept. of Family & Community Medicine, University of Toronto

Pain and Addiction Challenges in 2013

Canadian Guideline for Opioids for Chronic Non-Cancer Pain. Speaker Disclosure. Objectives. Canadian Guideline for Opioids for Chronic Non-Cancer Pain

Learning Objectives. Opioid Prescriptions in the US. The Opioid Epidemic

OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES

PART VI: TAPERING OPIOIDS ROBERT JENKINSON MD MARCH 7, 2018

Ethics Issue for Today

Subject: Pain Management (Page 1 of 7)

9/17/2014. Monitoring Controlled Substances. Objectives. Presription Painkiller Overdose

OPIOID ANALGESICS AND STIMULANT MEDICATIONS: A Clinician Guide to Prevent Misuse

Best Practices in Prescribing Opioids for Chronic Non-cancer Pain

The Role of Dentists in Preventing Opioid Abuse Tufts Health Care Institute Program on Opioid Risk Management 12 th Summit Meeting March 11-12, 2010

Chronic Disease Management for Pain: It CAN be done in primary care!

SUBSTANCE ABUSE IN THE ELDERLY. The Invisible Epidemic

Within the Scope of Practice/Role of _X APRN RN LPN CNA ADVISORY OPINION PAIN MANAGEMENT GUIDELIINES

Responding to The Joint Commission Alert on Safe Use of Opioids in Hospitals

PROVIDER BULLETIN. Published by Wyoming Workers Compensation Medical Case Management Unit October 21, 2015

Prescription Opioid Addiction

Disclosures. The Problem. The Problem. The Problem. The Problem. Buprenorphine Use in Combined Chronic Pain and Opioid Addiction

Guidelines for Management of Chronic Non- Malignant Pain

Responding to the Opioid Epidemic: Behavioral Health Specialists Role on the Interprofessional Team

Improving Safety in Opioid Prescribing: A Framework for Chronic Pain in Outpatient Practice

116 Journal of Pain and Symptom Management Vol. 41 No. 1 January 2011

What do they have in common?

MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St.

Screener and Opioid Assessment for Patients with Pain- Revised (SOAPP -R)

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015.

California. Prescribing and Dispensing Profile. Research current through November 2015.

6/11/2018. The Hidden Opioid Abuse Problem: Geriatric Opioid Abuse, or is Grandpa Really a Junkie. Learning Objectives. Case Study: Continued

Practical Pain Assessment- Screening for Psychosocial Risk. Session #3 Roman D. Jovey, MD

Safe Opioid Prescribing Practices in the Elderly

Appendix F Federation of State Medical Boards

Medication Misuse and Abuse: A Growing Epidemic

Monte H. Moore, MD. Idaho Physical Medicine and Rehabilitation. Meridian, ID

Readopt with amendment Med 502, effective (Document #11090), to read as follows:

ADDRESSING PRESCRIPTION PAIN MEDICINE ABUSE & MISUSE: A FRAMEWORK FORSAFE PRESCRIBING

Opioids and adjuvant analgesics in palliative care

Using CURES to combat prescription drug abuse/misuse

Managing Narcotics on Workers Comp Claims. Presented By: Craig S. Stern, PharmD, MBA President Pro Pharma Pharmaceutical Consultants, Inc.

9/23/2015. Chronic Pain and Addiction: Too Close for Comfort? Disclosures. Objectives. 45 y.o. Female Nurse. Question #1.

Opioid dependence: Detoxification

NBPDP Drug Utilization Review Process Update

Pain Management and Safe use of opioids in hospitals. Kyoung-Sil Kang, PharmD, BCPS Scott Tam, PharmD Lauve Casimir, RN, MSN

OPIOIDS AND NON-CANCER PAIN

Pain and Addiction. Edward Jouney, DO Department of Psychiatry

Pain Management in Persons with Substance Abuse

SAFE PRESCRIBING: THE PHYSICIAN S CHALLENGE. Elizabeth S. Grace, MD, FAAFP

Pain Management: Overview of A Practical Approach

Risk-Assessment Instruments for Pain Populations

Best Practices for Prescribing Controlled Substances

Analgesia for Patients with Substance Abuse Disorders. Lisa Jennings CN November 2015

Opioids Research to Practice

Medical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center

(Adapted with permission from the D-H Knowledge Map Primary Care Buprenorphine Guidelines)

Virginia. Prescribing and Dispensing Profile. Research current through November 2015.

The dog ate my methadone: Challenges in treating patients with advanced illness, pain, and addiction

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

``Considerations for using opioid drug therapy in workers compensation include patient safety, drug effectiveness and financial impacts

2/21/2018. What are Opioids?

Transcription:

Medication Use & Chronic Pain Control: Managing Tolerance, Dependence, Addiction & Aberrant Medication Taking Behavior Ernest J Dole, PharmD, PhC, FASHP, BCPS, CDE Pharmaceutical Care Coordinator ABQ Health Partners & Clinical Associate Professor UNM HSC College of Pharmacy Albuquerque, New Mexico Scenario 1 PO is a 50 y/o female w/ MRI proven bulging disk @ L4-L5 She received hydrocodone/apap 5/500 #28 (sig: 1 qid prn pain) 5 days ago She now calls you 2 days early for a refill and states the medication is not strong enough 1

Scenario 2 JS is a 54 y/o male w/ chronic low back pain secondary to degenerative disk disease. You have seen him for 2 years w/ no inappropriate behavior. He has been receiving hydrocodone/apap 5/500 1 qid prn pain for the past 2 years He calls you today stating that his medication was stolen during a family gathering at his house Scenario 3 RS is a 35 y/o male referred to your clinic for evaluation of chronic low back pain. He has been receiving hydrocodone/apap 5/500 1 qid prn pain per the chart notes. There have been several instances of lost/stolen prescriptions or requests for early refill of medication. Two weeks after his first visit w/ you RS calls stating that his medications were stolen and asks for an early refill 2

Scenario 4 GH is a 76 y/o male on hospice for small cell lung cancer. He has been receiving hydrocodone/apap 5/500 1 qid prn pain. GH calls for a refill of his pain medications and also asks for a refill of the morphine that you have been giving him. When you mention to him that you have not been prescribing morphine he hangs up. A review of his pharmacy profile reveals that he has been receiving morphine from numerous providers in town. Balancing Act 2.1 million adolescents 12 or older tried prescription medication for non-medical uses (SAMHSA 2007) The Joint Commission on Accreditation of Healthcare Organizations (JCAHO) has now officially recognized that pain is a major health problem and "patients have the right to appropriate assessment and management of pain" (JCAHO, 2000). Vicodin use in the past year was reported by 2.7 percent of 8th-graders, 7.2 percent of 10th-graders, and 9.6 percent of 12th-graders, remaining stable at relatively high levels for each grade. (NIDA webpage, 2008) 3

Thoughts to Consider Chronic pain is a chronic disorder & treatment of chronic pain is associated w/ predictable ADRS as w/ ANY other chronic condition Nothing gets better w/o diet & exercise Healing begins w/ a good nights sleep Nothing responds to medications alone Rarely does anything respond to only one medication; polypharmacy may be a good thing Maximize non-opiate solutions Thoughts to Consider The incidence of alcoholism and addiction in the general population is 5%-10% Therefore most healthcare providers ARE NOT alcoholics/addicts Differences in cross-cultural communication Differences in cross-cultural values Ability to suspend cultural values 4

Thoughts to Consider In patients w/ chronic pain also need to consider: Depression/Anxiety PMH of sexual or physical abuse/ptsd PMH of substance abuse/addiction PMH of ADD (~ 70% of pts w/ ADD have SUD) Obesity/Sleep apnea TSH level Thoughts to Consider Pain DOES NOT equal Percocet Many situations can be made worse by giving more medication Chronic administration of high dose (ie: 100 mg MSO4 or equivalent/day) may lead to chronic pain Decreased production of natural endorphins/enkephalins Increase in Na-dependent pain receptors Making of a Pain Cripple Analogy to steroids 5

Introduction Opioids and Chronic Pain: Efficacy Numerous studies demonstrate analgesic efficacy in chronic pain Typically relatively short in duration Benefit does not appear to be sustained over long period of time Continuous and long-term therapy often associated with loss of analgesic efficacy Ballantyne JC et al. Clin J Pain 2008. Introduction Key Terms and Concepts Physical Dependence Tolerance Opioid induced hypergesia Aberrant drug-related behavior Substance Misuse Abuse Addiction Pseudoaddiction 6

Definitions Physical Dependence Potential for abstinence on abrupt discontinuation or dose reduction, or administration of an antagonist Highly variable phenomenology Tachycardia, tachypnea Nausea/vomiting, diarrhea, abdominal cramps Sweating, rhinorrhea, piloerection Anxiety, insomnia Myalgias and arthralgias Definition Physical Dependence Not a problem if abstinence is avoided Theoretical connection to the genesis of addiction/relapse, but neither necessary nor sufficient Should never be labeled addiction 7

Tolerance Definition Declining effect with drug exposure Tolerance to side effects is desirable; tolerance to analgesia may be a problem Large clinical experience is reassuring Theoretical connection to the genesis of addiction/relapse, but neither necessary nor sufficient Should never be labeled addiction Definition Opioid Induced Hypergesia Paradoxical, abnormal pain secondary to prolonged use of opioids Possibly secondary to Decreased production of natural endorphins/enkephalins Increase in Na-dependent pain receptors 8

Definition Aberrant Drug-Related Behavior Problematic behaviors or red flags for clinicians Culture-bound, but defined by conventional practice, and by laws and regulations Should be viewed as data, which must be interpreted in a differential diagnosis of addiction Definition Aberrant Drug-Related Behavior (cont d) Aggressive complaining Drug hoarding when symptoms milder Requesting specific drugs Acquisition of drugs from other medical sources Unsanctioned dose escalation once or twice Use of the drug to treat another symptom Reporting unintended psychic effects Occasional impairment 9

Definition Aberrant Drug-Related Behavior (cont d) Selling prescription drugs Prescription forgery Stealing or borrowing drug from another person Injecting oral formulation Obtaining prescriptions from non-medical source Multiple episodes of prescription loss Concurrent abuse of related illicit drugs Multiple dose escalations despite warnings Repeated gross impairment or dishevelment Survey of Aberrant Drug-Related Behaviors (n = 388) 60 50 40 30 20 % of Patients ExhibitingAberrant Behaviors 10 0 0 2 to 3 3 to 4 5 to 7 8+ Number of Behaviors Reported Passik et al, Clin Ther, 2004 10

Substance Misuse Definition Use of any drug in a manner other than how it is indicated or prescribed Commonly includes running out early of medication or self-medication for reasons other than pain Abuse Definition Drug use outside of socially accepted norms Includes any use of an illicit drug and some degree of aberrant use of prescription drugs DSM IV: Psychoactive Substance Abuse A maladaptive pattern of drug use that results in harm or places the individual at risk 11

Addiction Definition Chronic disease with genetic, psychosocial, and environmental/situational influences, which can be induced in vulnerable people exposed to potentially abusable drugs DSM IV definition of substance dependence refers to addiction, but problematic in patients with chronic pain Definition Task Force of APS, AAPM, and ASAM: New definition of addiction A primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use compulsive use continued use despite harm craving 12

Pseudoaddiction Definition Aberrant drug-related behavior in patients reacting to under treatment of pain Diagnostic challenge: May co-exist with addiction or other psychiatric disorders Opioid Therapy: Judging Initial Risk Studies suggesting specific predictors of problematic use Prior history of substance abuse (Michna et al, J Pain Symptom Manage, 2004) Need to increase the dose, considering oneself addicted, and preference for a specific route (Compton et al, J Pain Symptom Manage, 1998) Focus on opioids during visits, need for early refills or dose escalation, multiple calls or early visits, other prescription problems, and obtaining opioids from other sources (Chabal et al, Clin J Pain, 1997) 13

Opioid Therapy: Judging Initial Risk Clinical experience suggests other factors: Family history of substance abuse Any major psychiatric pathology Heavy tobacco or alcohol use History of criminal activity History of physical/sexual abuse Contact with high risk people or environments Chaotic home situation Family history of major psychiatric pathology Opioid Therapy: Judging Initial Risk Most important factors: Prior history of substance abuse Family history of substance abuse Major psychiatric pathology 14

Opioid Therapy: Judging Initial Risk Future Predictors Presence or absence of PTSD Neurobiological markers Name A Sample of Validated Tools to Evaluate Risk Prescription Drug Use Questionnaire (PDUQ) Date 1998 Number of Questions 42 Type of Interview structured Screening Tool for Addiction Risk (STAR) 2003 14 self Pain Assessment and Documentation Tool (PDAT) 2004 41 structured Pain treatment Satisfaction Scale (PTSS) 2004 69 structured Satisfaction with Pain Medication (SPM) 2004 14 self Opioid Risk Tool (ORT) 2005 5 self Addiction Behaviors Checklist (ABC) 2006 20 structured Screener and Opioid Assessment for Patients with Pain (SOAPP) 2006 24/14 self Pain Medication Questionnaire (PMQ) 2006 26 self Current Opioid Misuse Measure (COMM) 2007 17 self 15

Contracts Data to Evaluate Risk Urine Tox Screens Databases NMBOP Controlled Substance Monitoring Program signing up & access Pharmacy records Previous chart notes My chart notes & experience Evaluation Personal and Family History How do you ask those questions? Open-ended questions mostly The format of the question may dictate the answer Remove stigma Ask specifics, not only if they used or when Last use, average use per week, most drank/used at a single sitting or single day Lost work or DUI/DWI 16

Evaluation (continued) Ongoing evaluation of aberrant behaviors Ongoing evaluation of medication use The 4 A s: (Passik et al) Analgesia ADLs Adverse Effects Abuse issues Principles of Management Assess the patient frequently Assess risk for opioid misuse/abuse frequent visits and small quantities For high-risk patients Provide written guidelines of expectations and responsibilities (treatment agreements) Urine drug screening Long-acting opioids with no rescue doses Consider referrals / consults Universal Precautions 17

10 Steps 1. Diagnosis with appropriate differential 2. Psychological assessment including risk of addictive disorders 3. Informed consent 4. Treatment Agreement 5. Pre- and Post- Intervention assessment of pain level and function * Trial of therapy discontinued if no benefit 10 steps (continued) 6. Appropriate trial of opioid medication + adjuvant medications 7. Regular reassessment of pain score and level of function 8. Regularly assess the 4 A s of pain * analgesia, adverse effects, aberrant behaviors, ADLs 9. Periodically review pain diagnosis and comorbid conditions (including addictive disorders) 10. Documentation 18

Pharmacologic Options Adjuvant Medications TCA, Dual-Acting Agents NSAID Muscle Relaxers Neuropathic Agents Tramadol Coming Attractions Imbedded Niacin Imbedded antagonists Tapentadol Non-Pharmacologic Options Non-Pharmacologic Options Injections: epidural, facet, trigger point Non-Traditional: chiropractor, massage, acupuncture SLEEP: evaluate for sleep apnea; utilize CPAP 19

Conclusion As with any medication therapy, use of opioids is a double-edged sword As with any chronic medication, safe and effective opioid therapy requires careful assessment and reassessment Aberrant drug taking behavior is a continuum of behaviors and a natural consequence of opioid therapy Numerous tool exist to assess patients at high risk; none in wide spread use; question efficacy in real-life practice settings Clinical experience may also be used to assess patients for high risk behavior In the future neurobiological marks may be widely used to predict those at high risk for aberrant behavior References Chou R et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain.2009;10:113-30. Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc. 2009;84:593-601. Weisner CM et al. Trends in prescribed opioid therapy for non-cancer pain for individuals with prior substance use disorders. Pain. 2009;7: Sullivan MD et al. Regular use of prescribed opioids: association with common psychiatric disorders. Pain. 2005;119;95-103. 20

References Sullivan MD et al. Association between mental health disorders, problem drug use and regular prescription opioid use. Arch Int Med.2006;166;2087-93. Wasan Ad et al. Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. Clin J Pain. 2007;23:307-15. Mancikanti L et al. Controlled substance abuse and illicit drug use in chronic pain patients: an evaluation of multiple variables. Pain Physician. 2006;9:215-26. Michna E et al. Predicting aberrant drug behavior in patients treated for chronic pain: Importance of abuse history. J Pain Symptom Manage. 2004;28:250-8. 21